Stakeholder Insight: Acute Stroke - TPA spurs infrastructure changes for the better

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2007-10-19

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Stroke is one of the top three leading causes of death worldwide and an area of high unmet needs. TPA is limited to a low number of ischemic stroke patients due to a short therapeutic time window, but it is still the best therapy available. TPA is responsible for major changes and advances in the way stroke patients are cared for, which is expected to evolve further.


Scope

  • Review of the available epidemiology data to assess the patient population of acute stroke.
  • Outline of the existing therapy options and the current prescribing trends.
  • Assessment of treatment outcomes and unmet needs associated with the outcomes.
  • Evaluation of the developmental agents in late stage clinical trials.


    • Report Highlights
    The incidence of stroke has been slowly declining over the last 50 years, as well as mortality from stroke. However, stroke continues to be a major public health concern, being the third leading cause of death in the US after heart disease and cancer, and the leading neurologic cause of long-term disability.

    The presently available tPA, while very efficacious, is to be used in acute ischemic stroke patients within the 3 hour time window since the onset of stroke symptoms. In order for more patients to be eligible for the treatment with the tPA, there should be more focus on significant infrastructure improvements in all of the major markets.

    There has been a lack of progress in acute stroke drug development. Over the last 20 years huge efforts have been expended in developing neuroprotectants. Over 100 reached clinical evaluation but none has clearly demonstrated efficacy. The agents currently in late stage development do not offer much hope in replacing or contributing to tPA therapy.


    Reasons to Purchase

  • target physicians more effectively, through an understanding of prescribing behavior and its influences.
  • validate new product forecasting based on diagnosis and treatment rates, and the likely rate of uptake for new products.
  • understand clinical trial requirements to prepare more effective NDAs.

    • Table of Contents

    Other users found this report page using the following search terms: stroke neuroprotection stroke tpa acute stay ischemic treatment average length hemorrhagic 2007

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.